Press release
Chronic Spontaneous Urticaria Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | GlaxoSmithKline, Allakos, Eli Lilly and Company, Roche, Novartis, Sanofi Pharma
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Spontaneous Urticaria pipeline constitutes 20+ key companies continuously working towards developing 20+ Chronic Spontaneous Urticaria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Chronic Spontaneous Urticaria Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Spontaneous Urticaria Market.
The Chronic Spontaneous Urticaria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Chronic Spontaneous Urticaria Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Chronic Spontaneous Urticaria treatment therapies with a considerable amount of success over the years.
*
Chronic Spontaneous Urticaria companies working in the treatment market are Yuhan Corporation, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, United BioPharma, Amgen, Celltrion, Novartis, and others, are developing therapies for the Chronic Spontaneous Urticaria treatment
*
Emerging Chronic Spontaneous Urticaria therapies in the different phases of clinical trials are- YH35324, TLL018, CDX-0159, UB-221, Tezepelumab, CT-P39, LOU064, and others are expected to have a significant impact on the Chronic Spontaneous Urticaria market in the coming years.
*
In March 2025, Experts highlighted how remibrutinib showed rapid and lasting effectiveness in the REMIX-1 and REMIX-2 trials, with significant improvements in disease activity scores (UAS7, ISS7, HSS7) beginning as early as week 1 and sustained through week 52. Nearly 50% of patients achieved complete symptom relief (UAS7 = 0) by the end of the study, all while maintaining a favorable safety profile throughout the trial duration.
*
In January 2025, Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotech company developing briquilimab-a novel antibody therapy targeting c-Kit (CD117) for mast cell-driven conditions like chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma-has announced encouraging preliminary results from its ongoing BEACON Phase 1b/2a study evaluating subcutaneous briquilimab in adult CSU patients.
Chronic Spontaneous Urticaria Overview
Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, is a persistent skin condition characterized by the recurrent appearance of hives (urticaria). These hives are red, raised, itchy welts or wheals that develop suddenly on the skin. When these hives occur for six weeks or more without any specific identifiable cause, it is termed as chronic.
Get a Free Sample PDF Report to know more about Chronic Spontaneous Urticaria Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight [https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Chronic Spontaneous Urticaria Drugs Under Different Phases of Clinical Development Include:
*
YH35324: Yuhan Corporation
*
TLL018: Hangzhou Highlightll Pharmaceutical Co., Ltd
*
CDX-0159: Celldex Therapeutics
*
UB-221: United BioPharma
*
Tezepelumab: Amgen
*
CT-P39: Celltrion
*
LOU064: Novartis Pharmaceuticals
Chronic Spontaneous Urticaria Route of Administration
Chronic Spontaneous Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Chronic Spontaneous Urticaria Molecule Type
Chronic Spontaneous Urticaria Products have been categorized under various Molecule types, such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Chronic Spontaneous Urticaria Pipeline Therapeutics Assessment
*
Chronic Spontaneous Urticaria Assessment by Product Type
*
Chronic Spontaneous Urticaria By Stage and Product Type
*
Chronic Spontaneous Urticaria Assessment by Route of Administration
*
Chronic Spontaneous Urticaria By Stage and Route of Administration
*
Chronic Spontaneous Urticaria Assessment by Molecule Type
*
Chronic Spontaneous Urticaria by Stage and Molecule Type
DelveInsight's Chronic Spontaneous Urticaria Report covers around 20+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Chronic Spontaneous Urticaria product details are provided in the report. Download the Chronic Spontaneous Urticaria pipeline report to learn more about the emerging Chronic Spontaneous Urticaria therapies [https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Chronic Spontaneous Urticaria Therapeutics Market include:
Key companies developing therapies for Chronic Spontaneous Urticaria are - GlaxoSmithKline, Allakos, Eli Lilly and Company, Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, and others.
Chronic Spontaneous Urticaria Pipeline Analysis:
The Chronic Spontaneous Urticaria pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Spontaneous Urticaria with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Spontaneous Urticaria Treatment.
*
Chronic Spontaneous Urticaria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Chronic Spontaneous Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Spontaneous Urticaria market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Chronic Spontaneous Urticaria drugs and therapies [https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Chronic Spontaneous Urticaria Pipeline Market Drivers
*
Increasing prevalence of Chronic Spontaneous Urticaria, development of Novel Treatments are some of the important factors that are fueling the Chronic Spontaneous Urticaria Market.
Chronic Spontaneous Urticaria Pipeline Market Barriers
*
However, difficulty in identifying the condition, lack of awareness about the treatment and other factors are creating obstacles in the Chronic Spontaneous Urticaria Market growth.
Scope of Chronic Spontaneous Urticaria Pipeline Drug Insight
*
Coverage: Global
*
Key Chronic Spontaneous Urticaria Companies: Yuhan Corporation, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, United BioPharma, Amgen, Celltrion, Novartis, and others
*
Key Chronic Spontaneous Urticaria Therapies: YH35324, TLL018, CDX-0159, UB-221, Tezepelumab, CT-P39, LOU064, and others
*
Chronic Spontaneous Urticaria Therapeutic Assessment: Chronic Spontaneous Urticaria current marketed and Chronic Spontaneous Urticaria emerging therapies
*
Chronic Spontaneous Urticaria Market Dynamics: Chronic Spontaneous Urticaria market drivers and Chronic Spontaneous Urticaria market barriers
Request for Sample PDF Report for Chronic Spontaneous Urticaria Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Chronic Spontaneous Urticaria Report Introduction
2. Chronic Spontaneous Urticaria Executive Summary
3. Chronic Spontaneous Urticaria Overview
4. Chronic Spontaneous Urticaria- Analytical Perspective In-depth Commercial Assessment
5. Chronic Spontaneous Urticaria Pipeline Therapeutics
6. Chronic Spontaneous Urticaria Late Stage Products (Phase II/III)
7. Chronic Spontaneous Urticaria Mid Stage Products (Phase II)
8. Chronic Spontaneous Urticaria Early Stage Products (Phase I)
9. Chronic Spontaneous Urticaria Preclinical Stage Products
10. Chronic Spontaneous Urticaria Therapeutics Assessment
11. Chronic Spontaneous Urticaria Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Chronic Spontaneous Urticaria Key Companies
14. Chronic Spontaneous Urticaria Key Products
15. Chronic Spontaneous Urticaria Unmet Needs
16 . Chronic Spontaneous Urticaria Market Drivers and Barriers
17. Chronic Spontaneous Urticaria Future Perspectives and Conclusion
18. Chronic Spontaneous Urticaria Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-spontaneous-urticaria-pipeline-2025-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-glaxosmithkline-allakos-eli-lilly-and-company-roche-novartis-sanofi-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Spontaneous Urticaria Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | GlaxoSmithKline, Allakos, Eli Lilly and Company, Roche, Novartis, Sanofi Pharma here
News-ID: 3969933 • Views: …
More Releases from ABNewswire

FiscalExpat.com Launches as Premier International Tax Intelligence Platform
Wyoming-Based Digital Publication Aims to Become Definitive Authority on Cross-Border Taxation
Cheyenne, Wyoming - Sep 30, 2025 - International taxation has never been more complex, and reliable guidance has never been harder to find. FiscalExpat.com (https://fiscalexpat.com [https://fiscalexpat.com/]) launches today as a comprehensive digital resource dedicated to helping expatriates, remote workers, and international professionals navigate the intricate world of cross-border tax compliance.
The platform addresses a critical gap in the market: the lack…

New Jersey Dentist Dr. Lee of Inspo Dental in Red Bank Offers Free Dental Care f …
Red Bank, NJ - Sep 30, 2025 - Inspo Dental, a leading New Jersey dental office in Red Bank, is giving back to the community with a special event dedicated to local heroes. On Wednesday, November 19th, 2025, Inspo Dental will host "For the Brave, From the Heart" -a free day of dentistry in New Jersey [https://www.inspodental.com/] for first responders and veterans, including police officers, firefighters, EMS, corrections officers, dispatchers,…

Tampa Attorney Offers Free Seminar to Help Families Avoid the Chaos of Planning …
The Faulkner Firm today announced a free community seminar aimed at helping Tampa-area families secure their futures and avoid the emotional and financial burden of unplanned estates. Titled "Don't Leave a Mess. Leave a Legacy," the event is a direct response to the staggering statistic that nearly half of all American adults lack basic estate planning documents.
Hosted by firm founder and attorney Debbie Faulkner, the workshop will provide a compassionate,…

Confidencias del corazon by Carlos Mavila: A Poetic Tribute to Love, Memory, and …
At a time when poetry is regaining its voice as a space of intimacy and reflection, Latin American poet Carlos Mavila V. A. presents Confidencias del corazon , the second volume of his Alma Poetica series. Now available worldwide on Amazon [https://www.amazon.com/Confidencias-coraz%C3%B3n-Alma-po%C3%A9tica-Spanish-ebook/dp/B0FMPNBM89/?utm_source=chatgpt.com], this book gathers seventy-six poems written across decades, a lyrical mosaic that portrays love in its many transformations-from passion to silence, absence to reconciliation, illusion to maturity.
A Journey…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…